Analysed GALECTIN THERAPEUTICS INC (GALT:NASDAQ) News Sources
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line
19-12-2025
yahoo.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders
22-01-2026
yahoo.com
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
26-02-2026
yahoo.com
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps
17-03-2026
marketbeat.com
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
17-03-2026
yahoo.com
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
31-03-2026
yahoo.com
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
11-05-2026
yahoo.com
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
15-05-2026
yahoo.com
What is the current price of GALECTIN THERAPEUTICS INC (GALT:NASDAQ)?
The current price of GALECTIN THERAPEUTICS INC (GALT:NASDAQ) is $2.86.
GALECTIN THERAPEUTICS INC (GALT:NASDAQ) absolute price change since previous trading day?
The absolute price change of GALECTIN THERAPEUTICS INC (GALT:NASDAQ) since the previous trading day is $0.22.
GALECTIN THERAPEUTICS INC (GALT:NASDAQ) percentage price change since previous trading day?
The percentage price change of GALECTIN THERAPEUTICS INC (GALT:NASDAQ) since the previous trading day is 8.3333%.
What is the most recent average sentiment score for GALECTIN THERAPEUTICS INC (GALT:NASDAQ)?
The most recent average sentiment score for GALECTIN THERAPEUTICS INC (GALT:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for GALECTIN THERAPEUTICS INC (GALT:NASDAQ)?
The most recent sentiment for GALECTIN THERAPEUTICS INC (GALT:NASDAQ) is .
SEC-8K** Filing Available For GALECTIN THERAPEUTICS INC (GALT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.